| Dr Edwin Shadzeka, MD | |
|
4314 Rustling Leaves Ter, Bowie, MD 20716-3608 | |
| (301) 806-2461 | |
| Not Available |
| Full Name | Dr Edwin Shadzeka |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 24 Years |
| Location | 4314 Rustling Leaves Ter, Bowie, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124213459 | NPI | - | NPPES |
| 101998675 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD432750 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph London | London, KY | Hospital |
| Middlesboro Arh Hospital | Middlesboro, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cogent Healthcare Of Kentucky, Psc | 0648294157 | 67 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
| Entity Name | Cogent Healthcare Of Kentucky, Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053362293 PECOS PAC ID: 0648294157 Enrollment ID: O20060124000434 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
| Entity Name | 24 On Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679522346 PECOS PAC ID: 5698688141 Enrollment ID: O20061012000513 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
| Entity Name | Ea Health Physicians Medical Group National Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427322981 PECOS PAC ID: 3173772340 Enrollment ID: O20150408000335 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720416555 PECOS PAC ID: 7719119965 Enrollment ID: O20210719003483 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edwin Shadzeka, MD 4314 Rustling Leaves Ter, Bowie, MD 20716-3608 Ph: (301) 806-2461 | Dr Edwin Shadzeka, MD 4314 Rustling Leaves Ter, Bowie, MD 20716-3608 Ph: (301) 806-2461 |
News Archive
Infants who are given antacids in their first year of life are more likely to fracture a bone later as a child, according to a new study published June 7 in Pediatrics.
Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.
A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology.
A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.
POZEN Inc., today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. (Teva) to resolve a U.S. patent infringement suit related to Teva's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of Treximet® (sumatriptan/naproxen sodium) marketed by POZEN's exclusive U.S. licensee, GlaxoSmithKline.
› Verified 7 days ago
Dr. Mariam Mcconnell Bahrami, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4379 Northview Dr, Bowie, MD 20716 Phone: 301-262-2627 Fax: 301-262-8411 | |
Dr. Sara Dereath Collins, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 16900 Science Dr Ste 200, Bowie, MD 20715 Phone: 410-573-9805 | |
Bai Kanu, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3233 Superior Ln, B 21, Bowie, MD 20715 Phone: 301-805-2500 Fax: 301-805-0114 | |
Sobhan A Mathew, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3048 Mitchellville Rd, Bowie, MD 20716 Phone: 301-218-1456 Fax: 301-218-1462 | |
Dr. David L Siegel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14999 Health Center Dr, Ste 201, Bowie, MD 20716 Phone: 301-262-8188 Fax: 301-464-8233 | |
Lizy Bose Thomas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14999 Health Center Dr, Suite 201, Bowie, MD 20716 Phone: 301-262-8188 Fax: 301-464-8233 |